Want to join the conversation?
$ACET said that its subsidiary Rising Pharmaceuticals is launching Olopatadine Hydrochloride 0.1% Ophthalmic Solution in U.S., generic version of Alcon's Patanol, which is used for the treatment of allergic conjunctivitis. According to IMS Health data, U.S. market sales for Olopatadine were about $223MM for the twelve months ended Sept. 30, 2015.
Shareholder alert..!! Rosen Law Firm has commenced an investigation into potential securities claims of $UHS. Shareholders please visit http://www.rosenlegal.com/cases-1008.html for more info.
Can we see "Made in the USA" label on iPhones in the near future? Heard that $AAPL is considering the idea of manufacturing iPhone in America.
People who are looking for a steady growth stock should take a look at $EME. This stock has never had a significant downfall in the last five years. Comfortably beats consensus target most of the time. Such potential, much wow!
Looks like Creative Planning jumped on the bandwagon! Increased its stake by 91% in $EWBC. A lot of companies recently raised their stack too. I smell something’s cooking.
Hey $DIS, you are better off with Princess Cinderella and Prince Charming. Sports just ain’t your thing! Maybe it’s time you listened to investors about the ESPN separation!